STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
B
Completed
- Adult Lymphocyte Depletion Hodgkin Lymphoma
- +5 more
- gemcitabine hydrochloride
- bendamustine hydrochloride
- Atlanta, Georgia
- +1 more
2021-10-21
Oct 21, 2021S
Completed
- Non-Hodgkin's Lymphoma
- bendamustine hydrochloride
- Kanagawa, Japan
- +3 more
2020-10-19
Oct 19, 2020J
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
Recruiting
- Recurrent Follicular Lymphoma
- Refractory Follicular Lymphoma
- Bendamustine Hydrochloride
- Brentuximab Vedotin
- Sacramento, CaliforniaUniversity of California Davis Comprehensive Cancer Center
2021-12-17
Dec 17, 2021U
Recruiting
- Classical Hodgkin Lymphoma
- +2 more
- Pembrolizumab
- Bendamustine Hydrochloride
- Toronto, Ontario, CanadaPrincess Margaret Cancer Centre
2021-12-31
Dec 31, 2021T
Not yet recruiting
- Amyloidosis
- Light Chain (AL) Amyloidosis
- Bendamustine Hydrochloride
- Isatuximab
- (no location specified)
2022-03-09
Mar 9, 2022W
Active, not recruiting
- Adult Lymphocyte Depletion Hodgkin Lymphoma
- +16 more
- 6,8-bis(benzylthio)octanoic acid
- bendamustine hydrochloride
- Winston-Salem, North Carolina
- +1 more
2021-10-28
Oct 28, 2021W
Recruiting
- Relapsed T-Cell Lymphoma
- +2 more
- CPI 613
- Bendamustine
- Winston-Salem, North CarolinaWake Forest Baptist Comprehensive Cancer Center
2021-08-27
Aug 27, 2021W
Active, not recruiting
- Mantle Cell Lymphoma
- Bendamustine
- +6 more
- Saint Louis, MissouriWashington University School of Medicine
2021-05-21
May 21, 2021Y
C
Completed
- Indolent B-Cell Non-Hodgkin's Lymphomas
- Bendamustine hydrochloride injection
- Fuzhou, Fujian, China
- +10 more
2020-09-25
Sep 25, 2020E
Active, not recruiting
- Recurrent Hodgkin Lymphoma
- +3 more
- Bendamustine
- +2 more
- Atlanta, Georgia
- +1 more
2021-08-25
Aug 25, 2021U
Completed
- Lymphoma, Non-Hodgkin
- Lymphoma
- Carfilzomib
- +2 more
- Davis, California
- +2 more
2021-04-21
Apr 21, 2021C
Not yet recruiting
- Lymphoma, Mantle-Cell
- Polatuzumab vedotin
- +2 more
- Brno, Czechia
- +6 more
2021-05-28
May 28, 2021K
Active, not recruiting
- Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
- +9 more
- BTK inhibitor PCI-32765
- +5 more
- Columbus, OhioOhio State University Medical Center
2021-02-20
Feb 20, 2021S
Completed
- Advanced Solid Tumor
- SyB C-0501
- Chuo-ku, Tokyo, Japan
- +1 more
2021-04-25
Apr 25, 2021M
Completed
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Bendamustine Hydrochloride
- +3 more
- Houston, TexasM D Anderson Cancer Center
2021-01-07
Jan 7, 2021S
Recruiting
- Myeloid Leukemia, Acute
- +3 more
- Bendamustine Hydrochloride
- Cyclophosphamid
- Saint Petersburg, Russian FederationRM Gorbacheva Research Institute
2022-04-04
Apr 4, 2022T
Completed
- Non-Hodgkin Lymphoma
- Bendamustine hydrochloride
- Beijing City, China
- +26 more
2021-11-05
Nov 5, 2021P
S
Recruiting
- Leukemia, Acute Lymphoblastic
- +5 more
- Fludarabine
- +5 more
- Saint Petersburg, Russian FederationRM Gorbacheva Research Institute
2021-06-21
Jun 21, 2021M
Terminated
- Follicular Lymphoma
- Bendamustine
- +2 more
- Houston, TexasUniversity of Texas MD Anderson Cancer Center
2020-04-01
Apr 1, 2020S
Completed
- Hodgkin's Lymphoma
- Nivolumab
- Bendamustine Hydrochloride
- Saint-Petersburg, Russian FederationFirst Pavlov State Medical University of St. Petersburg
2020-05-27
May 27, 2020S
Completed
- Diffuse Large B Cell Lymphoma
- Bendamustine hydrochloride
- +5 more
- Saint-Petersburg, Russian FederationFirst Pavlov State Medical University of St. Petersburg
2021-06-02
Jun 2, 2021M
Completed
- Refractory Multiple Myeloma
- bendamustine hydrochloride
- +2 more
- Duarte, California
- +4 more
2020-02-10
Feb 10, 2020S
Completed
- Non-Hodgkin's Lymphoma
- +3 more
- SyB L-0501
- Rituximab
- Nagoya-city, Aichi, Japan
- +3 more
2021-07-01
Jul 1, 2021